Dr. Kuzel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
15300 West Ave
Robert H Lurie Comp Ca Ctr
Orland Park, IL 60462Phone+1 708-226-2513Fax+1 312-942-3192- Is this information wrong?
Summary
- I am the Samuel G Taylor III Professor of Oncology, and the Chief of the Division of Hematology/Oncology and Cell Therapy at Rush University since June 2016. Prior to that I spent 26 years as a Professor of Medicine and Dermatology in the Division of Hematology/Oncology at Northwestern University, Feinberg School of Medicine. I have focused my career on the design and execution of clinical trials with a specific focus on experimental therapeutics, especially phase I and phase II therapeutics rationally designed to exploit molecular and/or protein alterations within tumor cells and immunotherapeutic approaches/agents. Agents utilized have included chemotherapy drugs, targeted agents, cytokines, vaccines, and other novel immunotherapeutics. I have been a Co-PI on a SPORE in Prostate Cancer at Northwestern focused on immunomodulation to reverse resistance to oral novel anti-androgen therapies (the grant is in NCE thru Aug 2021). I have also had Prostate Cancer Foundation and NIH funding for translational agent development. I also worked in the area of shared decision making and identification of adverse events associated with drug therapy of cancer. I have served on a number of NCI site visit teams as a reviewer for Program Projects for 1) Immunotherapy in renal cell Ca, 2) Melanoma with dendritic cell-based immunotherapy approaches, and 3) Cellular immunotherapy, as well as 4) Community based NCI centers (NCOROP), and Novel Statistical Clinical Programs. In addition, I participated on several NCCN guidelines committees including Kidney/Testis and Bladder and Prostate at various times. I serve on multiple Data Monitoring Committees of phase II and III global check point inhibitor clinical trials.
Education & Training
- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1987 - 1990
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1984 - 1987
- University of Michigan Medical SchoolClass of 1984
- University of MichiganBA, Biomedical Sciences, Cum Laude, 1978 - 1981
- University of MichiganB.S., Biomedical Sciences, 1981
Certifications & Licensure
- IL State Medical License 1984 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Chicago Magazine: Top Doctors Castle Connolly, 2008, 2010, 2012, 2014, 2016, 2018, 2020
- America's Top Doctors Castle Connolly, 2008-2017
- America's Top Doctors for Cancer Castle Connolly, 2007-2017
- Join now to see all
Clinical Trials
- Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome Start of enrollment: 1991 Oct 01
- Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1999 May 20
- Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome Start of enrollment: 1998 May 01
- Join now to see all
Publications & Presentations
PubMed
- Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therap...Ferrari, M., Jimenez-Uribe, A., Wang, L., Hoeppner, L., Hahm, E., Yu, J., Gradilone, S., Mansini, A., Murugan, P., Kuzel, T.> ;Oncogene. 2024 Feb 1
- 2 citationsReduced Bioactive Microbial Products (Pathogen-Associated Molecular Patterns) Contribute to Dysregulated Immune Responses and Impaired Healing in Infected Wounds in Mi...Ruchi Roy, Foyez Mahmud, Janet Zayas, Timothy M Kuzel, Jochen Reiser, Sasha H Shafikhani> ;The Journal of Investigative Dermatology. 2024 Feb 1
- Minimum thresholds deemed acceptable by patients and physicians for sensitivity and specificity of mobile skin cancer screening algorithms.Bianca Kang, Rachel E Christensen, McKenzie A Dirr, Umer Nadir, Joaquin C Brieva, M Laurin Council, Jeffrey S Dover, Timothy M Kuzel, Kira Minkis, Bharat B Mittal, Jef...> ;Journal of the American Academy of Dermatology. 2023 Sep 1
- Join now to see all
Journal Articles
- Type 2 Innate Lymphoid Cells Impede IL-33–Mediated Tumor SuppressionTimothy M Kuzel, Bin Zhang, The Journal of Immunology
- The Present and Future Cardiovascular Medicine and Society the Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (Or Onco-Cardiology) and Call to ActionAgne Paner, Hena Patel, Timothy Kuzel, Parameswaran Venugopal, Tochi M Okwuosa, Nicole Prabhu, Kim A Williams, ScienceDirect
- The efficacy of lenvatanib and everolimus in Chromophobe-type non-Clear Cell Renal Cell Cancer: A case report and Literature reviewSchwartz C, Pfanzelter N, Kuzel TM, Clin Genitourin Cancer, 1/25/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-HodgkinÍs LymphomaTimothy M. Kuzel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Comparing association of trans rectal ultrasound prostate weight with actual prostate weight obtained after radical prostatectomy after adjustment for other prognostic...Helenowski, I.B., Jovanovic, B.D., Gurley, M.J., Leikin, R.G., Catalona W.J., Rosten, A.B., Kuzel, T.M., Proceedings of the American Physical Society, New Orleans, LA, 1/1/2017
- Updated Analyses of the International, Open-label, Randomized, Phase 3 ALCANZA Study: Longer-term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate o...Julia Scarisbrick, Steven M. Horwitz, Reinhard Dummer, Madeleine Duvic, Youn H. Kim, Jan Walewski, Sean Whittaker, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, ..., Proceedings of the American Society of Hematology, Atlanta, GA, 1/1/2017
- Join now to see all
Lectures
- Updated Analyses of the International, Open-label, Randomized, Phase 3 ALCANZA Study: Longer-term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate o...London, United Kingdom - 1/13/2017
- Immunotherapy of Cancer1/1/2012
- A phase 2 mutli-center, randomized, open-label study of two dose levels of IMO-2055 in Patients with metastatic or recurrent Renal Cell Carcinoma.1/1/2009
- Join now to see all
Other
- The use of Gemcitabine in metastatic urothelial transitional cell cancerKuzel TM and Stadler WM, Lilly Monograph
1/1/1996 - Book Review of --Atkins MB and Mier JW. Therapeutic Applications of Interleukin-2.Kuzel TM, Doody's Health Sciences Book Review Annual
1/1/1993 - Interferons: Basic Principles and Clinical Applications.Kuzel TM. Book Review of --Estrov Z, Kurzock R, and Talpaz M, Doody's Health Sciences Book Review Annual
1/1/1993
Press Mentions
- Rush Earns ASCO QOPI Certification for High-Quality Cancer CareSeptember 5th, 2019
- Personalized Vaccine Helps Patients Fight Ovarian CancerApril 12th, 2018
- Vaccine Giving New Hope in Fight Against CancerFebruary 9th, 2018
- Join now to see all
Professional Memberships
- Member
- Fellow
Hospital Affiliations
- Rush University Medical CenterChicago, Illinois
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: